UY27928A1 - Formas cristalinas de (4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil)-amida del ácido quinoxalina-2-carboxílico - Google Patents

Formas cristalinas de (4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil)-amida del ácido quinoxalina-2-carboxílico

Info

Publication number
UY27928A1
UY27928A1 UY27928A UY27928A UY27928A1 UY 27928 A1 UY27928 A1 UY 27928A1 UY 27928 A UY27928 A UY 27928A UY 27928 A UY27928 A UY 27928A UY 27928 A1 UY27928 A1 UY 27928A1
Authority
UY
Uruguay
Prior art keywords
methyl
quinoxaline
fluorobencil
dihidroxi
octil
Prior art date
Application number
UY27928A
Other languages
English (en)
Inventor
Christopher Stanley Poss
John Charles Kath
Zheng Jane Li
Zhengong Bryan Li
Eric Brock Mcelroy
Clifford Nathaniel Meltz
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY27928A1 publication Critical patent/UY27928A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a formas cristalinas de (4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil)-amida del ácido quinoxalina-2-carboxílico, útiles en el tratamiento o prevención de un trastorno o afección por medio de la antagonización del receptor CCR1, y a sus métodos de preparación y uso.
UY27928A 2002-08-12 2003-08-05 Formas cristalinas de (4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil)-amida del ácido quinoxalina-2-carboxílico UY27928A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40321602P 2002-08-12 2002-08-12

Publications (1)

Publication Number Publication Date
UY27928A1 true UY27928A1 (es) 2004-03-31

Family

ID=31715961

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27928A UY27928A1 (es) 2002-08-12 2003-08-05 Formas cristalinas de (4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil)-amida del ácido quinoxalina-2-carboxílico

Country Status (22)

Country Link
US (1) US20040072834A1 (es)
EP (1) EP1539715A1 (es)
JP (1) JP2005538130A (es)
AP (1) AP2005003226A0 (es)
AR (1) AR040839A1 (es)
AU (1) AU2003250450A1 (es)
BR (1) BR0313378A (es)
CA (1) CA2494776A1 (es)
EC (1) ECSP055588A (es)
GT (1) GT200300169A (es)
IL (1) IL166548A0 (es)
IS (1) IS7674A (es)
MX (1) MXPA05001781A (es)
NO (1) NO20050540L (es)
OA (1) OA12894A (es)
PA (1) PA8580401A1 (es)
PE (1) PE20040866A1 (es)
TN (1) TNSN05035A1 (es)
TW (1) TW200407316A (es)
UY (1) UY27928A1 (es)
WO (1) WO2004014875A1 (es)
ZA (1) ZA200500768B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2516416A1 (en) 2009-12-23 2012-10-31 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130259830A1 (en) 2010-07-12 2013-10-03 Ironwood Pharmaceuticals, Inc. Crth2 modulators
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CN102276539B (zh) * 2011-06-29 2013-08-14 赵雪梅 一种具有抑菌作用的化合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (es) * 1962-12-19
US3492397A (en) * 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) * 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) * 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) * 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
BR9807858A (pt) * 1997-02-26 2000-02-22 Pfizer Derivados de amida do ácido heteroaril-hexanóico, suas preparaçÊes e seus usos como inibidores seletios de mip-1.alfa ligando aos seus receptores ccr1
KR100385529B1 (ko) * 1998-02-05 2003-05-27 화이자 프로덕츠 인코포레이티드 신규 디하이드록시헥산산 유도체

Also Published As

Publication number Publication date
ECSP055588A (es) 2005-04-18
BR0313378A (pt) 2005-07-12
JP2005538130A (ja) 2005-12-15
GT200300169A (es) 2004-05-12
EP1539715A1 (en) 2005-06-15
IL166548A0 (en) 2006-01-15
TNSN05035A1 (fr) 2007-05-14
NO20050540L (no) 2005-03-10
IS7674A (is) 2005-01-27
MXPA05001781A (es) 2005-04-25
ZA200500768B (en) 2006-07-26
AR040839A1 (es) 2005-04-20
US20040072834A1 (en) 2004-04-15
TW200407316A (en) 2004-05-16
PA8580401A1 (es) 2004-02-16
AP2005003226A0 (en) 2005-03-31
OA12894A (en) 2006-10-13
WO2004014875A1 (en) 2004-02-19
CA2494776A1 (en) 2004-02-19
PE20040866A1 (es) 2004-11-26
AU2003250450A1 (en) 2004-02-25

Similar Documents

Publication Publication Date Title
PA8579601A1 (es) Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas
CL2006003736A1 (es) Compuestos derivados de triazina o pirimidina sustituida, antagonistas del receptor de prokineticina 1, composicion farmaceutica; y uso en el tratamiento de trastornos gastrointestinales.
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
CR8891A (es) Antagonismo de la actividad del receptor de interleuquina 21
WO2005102396A3 (en) Multimodality nanostructures, methods of fabrication thereof, and methods of use thereof
SG167664A1 (en) 2,4-pyrimidinediamine compounds and their uses
CL2007003155A1 (es) Compuestos derivados de 3,7-diazabiciclo[3.3.0]octano o 3,7-diazabiciclo[3.3.1]nonano, moduladores de receptores nicotinicos neuronales; composicion farmaceutica; y uso en el tratamiento de trastornos del snc.
DK1094816T3 (da) Biphenylsulfonamider som dobbelte angiotensin-endothelin-receptorantagonister
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
CL2008001920A1 (es) Composicion farmaceutica que comprende un inhibidor de la pde 2, un agonista del receptor selectivo e2 y un portador; y uso en el tratamiento de fractura y/o defecto oseo (div. sol. 3179-04).
WO2007073497A3 (en) Calcium channel antagonists
AR037109A1 (es) Uso de flibanserina
EA200701845A1 (ru) Рофлумиласт для лечения сахарного диабета
NO20054371L (no) Somatostatin-dopamin kimaere analoger
DE60230722D1 (de) Il-8-rezeptor-antagonisten
CL2003001415A1 (es) Compuestos d derivados de naftil, quinolinil e isoquinolinil urea; composicion farmaceutica; y uso en el tratamiento y prevencion de condiciones de dolor y en el sibndrome del colon irritable y condiciones asociadas.
BR0315644A (pt) Piperazinil e diazapanil benzamidas e benzotioamidas
ECSP055588A (es) Formas cristalinas de [4-carbamoil-1-(3-fluorobencil)-2,7-dihidroxi-7-metil-octil]-amida del ácido quinoxalina-2-carboxilico
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
UY26601A1 (es) Antagonistas de los receptores de il-8
SE0302304D0 (sv) Novel compounds
DK1383742T3 (da) Syntese og fremgangsmåder til anvendelse af tetrahydroindolonanaloge og derivater
ES2171196T3 (es) Uso de antagonistas del receptor cck-b para el tratamiento de trastornos del sueño.
CL2003001360A1 (es) Compuestos derivados de pirazol, composicion farmaceutica, agonistas o antagonistas selectivos dl receptor cck-1, utiles para el tratamiento de trastornos gastrointestinales y del sistema nervioso central.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150429